Valence 로고
인기
로그인
Loading data for GPCR — first visit, this takes a few seconds.

관심목록에 추가

Structure Therapeutics In...

NasdaqGM: GPCR · 실시간 가격 · USD
54.01
-0.69 (-1.26%)
종가 기준: Aug 18, 2026, 3:59 PM

Structure Therapeutics Inc. (GPCR) Stock Price, Analysis & Data

-1.26%
매수호가36.54
시가총액3.78B
매출 (ttm)n/a
순이익 (ttm)-214.84M
베타-1.51
EPS (ttm)-3.03
P/E (ttm)n/a
선행 P/E-25.04
P/B (ttm)2.47
P/S (ttm)n/a
Earnings DateNov 5, 2026
매도호가64
거래량66,112
평균 거래량 (20일)714,545
시가54.61
전일 종가54.70
일중 범위53.51 - 54.79
52주 범위18.26 - 94.90
애널리스트n/a
목표주가n/a
배당n/a
배당락일n/a

GPCR 소개

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions. Th...

[더 보기]
산업 Biotechnology
섹터 Healthcare
IPO 일자 Feb 3, 2023
직원 수 281
상장 거래소 NasdaqGM
티커 GPCR
웹사이트 https://structuretx.com
전체 기업 정보

재무 실적

2025년 Structure Therapeutics의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -141.2M로, 15.24% 증가했습니다.

재무제표

어닝 서프라이즈

Structure Therapeutics가 Aug 6, 2026에 분기 실적을 발표했습니다:
  • 매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.
  • EPS -0.49 예상치 하회 -0.11, 및 -36.11% 전년 대비 감소.

    • 다음 실적 발표

    Structure Therapeutics Inc.의 실적 발표 예정일은 Nov 5, 2026, 정규장 중입니다.
    애널리스트 예상 매출은 ... 업그레이드
    news image

    1개월 전 · Insider Monkey

    Structure Therapeutics (GPCR) Is A Hidden Biotech Multibagger Stock To Buy Now

    Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the 8 Hidden Multibagger Stocks to Buy Now. On June 7, Cantor Fitzgerald analyst Prakhar Agrawal reiterated a Buy rating on Structure Therapeutics I...

    news image

    1개월 전 · 24/7 Wall St.

    After Apogee, 3 More Biotech Buyout Targets Wall Street Can’t Stop Watching

    Big Pharma's patent cliffs are forcing acquirers to hunt for revenue-producing biotech assets before rivals snap them up, and three names keep surfacing in deal speculation. One already has a natural ...

    news image

    2개월 전 · Insider Monkey

    H.C. Wainwright Reiterates Buy Rating for Structure Therapeutics (GPCR)

    Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the 10 best mid-cap stocks that could double your money. On June 11, H.C. Wainwright reduced its price target on Structure Therapeutics Inc. (NASDAQ...

    news image

    2개월 전 · Insider Monkey

    Structure Therapeutics (GPCR) Reports Positive Phase 2 Weight Loss Data for Aleniglipron

    Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the oversold stocks to buy right now. Structure Therapeutics reported positive Phase 2 results for its oral GLP-1 receptor agonist, aleniglipron, sh...

    news image

    2개월 전 · Simply Wall St.

    Does Phase 2b Oral GLP-1 Data on Aleniglipron Change The Bull Case For Structure Therapeutics (GPCR)?

    Structure Therapeutics recently reported in Nature Medicine and at the American Diabetes Association’s 86th Scientific Sessions that its oral GLP-1 receptor agonist aleniglipron achieved statistically...

    2 페이지 중 1